Sanofi CEO Chris Viehbacher may be reconsidering his November plans to spend just €1 billion to €2 billion per year on acquisitions. Rumor has it the drug giant is eyeing a bid for Merck's OTC unit, which could sell for up to $12 billion.
GE Healthcare completed its acquisition of three Thermo Fisher Scientific units. The $1.1 billion deal gives GE access to Thermo Fisher's profitable cell culture, gene modulation and magnetic bead businesses, helping the company expand its presence in protein analysis and medical diagnostics.
AMRI has inked a deal to trade $41 million for contract manufacturer Cedarburg Pharmaceuticals, looking to broaden its capabilities in the sector and home in on API production.
Germany's Evotec has signed a deal to buy up a biopharma asset management company and get its hands on some promising drug candidates, broadening its novel approach to the CRO game by adding some unpartnered assets to its stable of collaborations.
Not long after digesting its $450 million buyout of BioFire Diagnostics, bioMérieux seems to be on the hunt for another acquisition. Reuters reported recently that the French company is eyeing Siemens' microbiology unit.
Back in January, Valeant Pharmaceuticals' CEO J. Michael Pearson couldn't say how he intended to reach his lofty goal of cracking the list of top 5 drugmakers worldwide. Now, he's offering new details about his acquisition blueprints, and they include deals in ophthalmology, dermatology and dentistry.
Yet another U.S. drugmaker is headed to Ireland to enjoy the tax benefits. Horizon Pharma is doing a reverse merger with Vidara Therapeutics International in a deal that it says speeds its path to profitability. And where is Vidara based? Dublin.
Should Salix Pharmaceuticals snap up its North Carolina neighbor Furiex Pharmaceuticals? The latter's bowel drug could slide right in to Salix's business, analysts said. And Furiex is scouting around for a potential buyer, Bloomberg reports.
Private equity outfit GTCR has recruited two industry veterans and put up $300 million to create Maravai Life Sciences, a buyout-focused firm out to make some deals.
Five years after optioning the right to buy Proteon Therapeutics for up to $550 million, Novartis has walked away from the table despite what Proteon says was a successful study of its blood vessel-dilating drug, leaving the biotech to fend for itself as it prepares for Phase III.